Flebogamma 5% DIF

immune globulin intravenous (human), 5% solution (dual inactivation and filtration) · Instituto Grifols, S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Flebogamma 5% DIF, covering 2025-12-05 to 2025-12-05. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome [Phase 2, Phase 3]

See pricing